Boehringer Ingelheim bags ViraT in €210m deal
EMBL Ventures has announced that its portfolio company ViraTherapeutics is set to be acquired by Boehringer Ingelheim in a €210m million (US$245m) transaction.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2082 entries already.
Entries by Thomas Gabrielczyk
EU approves Shire’s van Willebrand factor
Orphan drug leader Shire plc has been granted EU marketing authorization for its recombinant van Willebrand factor (rVWF) vonicog alfa as second-line treatment for van Willebrand disease, the most common blot clotting disorder..
PD1/PD-L1blockers trigger metastases
Drug Developers dealing with PD1-PDL1 checkpoint inhibitors must consider new safety problems associated with the hyped cancer meds.
EIB incentivises bioeconomy investments
The European Investment Bank (EIB) has issued its first Sustainability Awareness Bond worth €500m to support investments into water projects – health and nutrition to follow.
The future of agrochemistry
One of the world’s largest and most controversial mergers in the past few years was sealed in early June. German pharma and chemistry company Bayer has taken over US competitor Monsanto, forming the largest integrated provider of seeds, agrochemicals and digital farming solutions on the planet. The acquisition is part of a recent US$170bn deal binge that is already having a profound impact on the future of global agriculture.
New antibiotics on the block
Around 300 international AMR experts met at ESCMID-ASM drug development conference in Lisbon to discuss the latest progress in the field.
Adaptimmune raises US$100m
Oxford-based Adaptimmune Therapeutics plc has raised US$100m in a registered direct offering of American Depositary Shares (ADS).
CAR-Ts: Novartis wins UK
The NHS England announces it will reimburse Novartis’ CAR-T cell therapy Kymriah as treatment for children with B cell acute lymphoblastic leukemia (ALL) that are refractory, in relapse post-transplant or in second or later relapse.
Evox raises €37m in Series B round
Exosome drug delivery specialist Evox Therapeutics Ltd has closed a €37.1m (£35.5m) Series B financing round led by Redmile Group and significant contributions from GV (Google Ventures) and Cowen Healthcare Investments.
Sanofi gets the EU’s ok for caplacizumab
The EU approved Sanofi’s Cablivi (caplacizumab) as the first antibody therapeutic to treat acquired thrombotic thrombocytopenic purpura (aTTP) on Friday.